使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings. Welcome to the Align third quarter 2026 earnings call. (Operator Instructions) Please note, this conference is being recorded.
各位好。歡迎參加 Align 2026 年第三季財報電話會議。(接線員指示) 請注意,本次會議將被錄音。
I will now turn the conference over to your host, Shirley Stacy, with Align Technology. You may begin.
現在我將把會議交給本次主持人、Align Technology 的 Shirley Stacy。您可以開始了。
Shirley Stacy - Vice President - Corporate Communications & Investor Relations
Shirley Stacy - Vice President - Corporate Communications & Investor Relations
Good afternoon. Thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO. We issued third quarter 2026 financial results today via Business Wire, which is available on our website at investor.aligntech.com.
各位下午好。感謝各位加入我們。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同參與電話會議的有總裁暨執行長 Joe Hogan,以及財務長 John Morici。我們已於今日透過 Business Wire 發布 2026 年第三季財務結果,並可在我們的網站 investor.aligntech.com 查閱。
Today's conference call is being audio webcast and will be archived on our website for approximately one month. As a reminder, the information provided and discussed today will include forward-looking statements, including statements about Align's future events, product outlook and financial expectations. These forward-looking statements are only predictions and involve risks and uncertainties that are described in more detail in our most recent periodic reports filed with the Securities and Exchange Commission available on our website and at sec.gov. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statement. We've posted historical financial statements with corresponding reconciliations, including our GAAP to non-GAAP reconciliation, if applicable, and our third quarter 2026 conference call slides on our website under Quarterly Results. Please refer to these files for more detailed information.
今天的電話會議將以音訊方式網路直播,並將在我們網站上封存約一個月。提醒各位,今天提供與討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望與財務預期的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容在我們最近向美國證券交易委員會提交的定期報告中有更詳細的說明,該等報告可於我們網站及 sec.gov 查閱。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述的義務。我們已在網站「季度業績」專區張貼歷史財務報表及相應調節表(如適用,包括 GAAP 與非 GAAP 的調節),以及 2026 年第三季電話會議簡報。請參閱這些檔案以取得更詳細資訊。
With that, I'd like to turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我想把電話會議交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?
Joseph Hogan - Chief Executive Officer, President, Director
Joseph Hogan - Chief Executive Officer, President, Director
Thanks, Shirley. Good afternoon, and thanks for joining us. On today's call, I'll review our third quarter performance and the growth priorities we're executing across Align. John will then discuss our financial results and outlook for Q4 and fiscal 2026. Before we start, I'd like to note that we announced our CEO Succession Plan earlier today.
謝謝,Shirley。各位下午好,感謝各位加入我們。在今天的電話會議中,我將回顧我們第三季的表現,以及我們在 Align 全面推動的成長優先事項。接著 John 將說明我們的財務結果,以及第四季與 2026 會計年度的展望。在開始之前,我想先提到我們今天稍早已宣布執行長接班計畫。
I'll return to this topic at the end of the call. For now, let's focus on our third quarter results. We delivered solid third quarter results with record doctor submitters, record third quarter Clear Aligner shipments, improved utilization and broad-based international growth. Worldwide revenue was $1.015 billion, up 1.9% year-over-year or 2.4% at a constant currency and in line with our outlook. Clear Aligner shipments increased 6.6% and to 691,000 at the high end of our expectation for mid-single-digit growth in Q3.
我會在電話會議結尾再回到這個主題。現在先聚焦於第三季的結果。我們第三季交出穩健成果:醫師提交數創新高、第三季 Clear Aligner 出貨量創新高、利用率提升,以及國際市場廣泛成長。全球營收為 10.15 億美元,年增 1.9%,以固定匯率計年增 2.4%,並符合我們的展望。Clear Aligner 出貨量成長 6.6%,達 69.1 萬件,位於我們對第三季中個位數成長預期的高端。
In Systems and Services, revenue was $175.5 million, down 7.6% year-over-year and generally consistent with the guidance we provided at Q2. Reported revenue continues to reflect a shift towards lower-priced scanner configurations and more flexible acquisition models and stable ASP on a like-for-like basis, while our installed base and customer footprint continue to expand.
在系統與服務(Systems and Services)方面,營收為 1.755 億美元,年減 7.6%,整體與我們在第二季提供的指引大致一致。已報告營收持續反映產品組合轉向較低價格的掃描器配置與更彈性的取得模式;在同類比較基礎上 ASP 維持穩定,同時我們的裝機基礎與客戶覆蓋範圍持續擴大。
From a profitability perspective, non-GAAP gross margin was 70.4%, modestly below our expectation, reflecting higher fuel-related transportation costs, lower Clear Aligner ASP and the impact of geographic and product mix. Disciplined expense management and productivity improvements contributed to non-GAAP operating profit margin of 24.4%, above our outlook.
從獲利角度來看,非 GAAP 毛利率為 70.4%,略低於我們的預期,主要反映燃油相關運輸成本較高、Clear Aligner ASP 較低,以及地理與產品組合的影響。嚴謹的費用管理與生產力提升,帶動非 GAAP 營業利益率達 24.4%,高於我們的展望。
Overall, Q3 demonstrated our ability to execute in a challenging environment, delivering continued Clear Aligner growth, expanding our digital platform and consumer footprint and improving profitability. We remain focused on continuing to drive growth and building on this progress across several key areas. We continue to drive adoption utilization across customer channels. That includes increasing utilization among orthodontists, expanding Invisalign adoption among GP dentists and growing with DSOs and strategic accounts.
整體而言,第三季展現了我們在充滿挑戰的環境中執行的能力:持續推動 Clear Aligner 成長、擴大我們的數位平台與消費者觸及,並提升獲利能力。我們仍專注於持續推動成長,並在數個關鍵領域延續這些進展。我們持續推動各客戶通路的採用與利用率提升。這包括提高矯正專科醫師的利用率、擴大一般牙醫(GP)對 Invisalign 的採用,以及與 DSO 與策略性客戶共同成長。
During Q3, a record 91,000 doctors submitted Invisalign cases, up more than 3% year-over-year, while overall utilization increased 3.4%. We are expanding the patients and clinical needs that we address. Younger patients remain one of our largest growth opportunities and were again an important contributor to our Q3 performance. Younger patient shipments increased at a double-digit rate in international markets with strong teen performance across APAC and EMEA.
第三季共有創紀錄的 9.1 萬名醫師提交 Invisalign 病例,年增超過 3%,同時整體利用率提升 3.4%。我們正在擴大可服務的患者族群與臨床需求。年輕患者仍是我們最大的成長機會之一,並再次成為第三季表現的重要貢獻來源。在國際市場,年輕患者出貨量以雙位數成長,亞太(APAC)與歐洲、中東及非洲(EMEA)的青少年表現強勁。
Our growing patient portfolio, including Invisalign First, Invisalign Palatal Expander and Mandibular Advancement with Occlusal Blocks enables doctors to address younger and more complex patients while expanding the range of orthodontic needs that can be addressed with Invisalign treatment. Affordability and patient conversion continue to be an important focus for us. Our Zero Additional Aligner offering providing doctors with a greater treatment and pricing flexibility while patient financing and commercial programs are designed to help practices convert more prospective patients.
我們持續擴大的患者產品組合,包括 Invisalign First、Invisalign Palatal Expander,以及搭配咬合墊(Occlusal Blocks)的下顎前移(Mandibular Advancement),使醫師能夠處理更年輕且更複雜的患者,同時擴大 Invisalign 治療可涵蓋的矯正需求範圍。可負擔性與患者轉換率仍是我們的重要聚焦。我們的 Zero Additional Aligner 方案為醫師提供更大的治療與定價彈性;同時,患者融資與商業方案旨在協助診所將更多潛在患者轉化為實際治療患者。
Worldwide Zero AA volume increased triple digits year-over-year during Q3. We're also continuing to expand the value of the Align Digital platform. The opportunity goes beyond Clear Aligners or scanner placements individually. We are connecting iTero, scanning diagnostics, AI-enabled treatment planning, Invisalign treatment, exocad restorative workflows and practice applications to create a more integrated digital workflow for doctors and patients. This also represents a growth opportunity beyond traditional orthodontics. Through dental laboratories, we can reach GP dentists more broadly and enable digital workflows that integrate tooth movement with restorative treatment and planning.
第三季全球 Zero AA 量年增達三位數。我們也持續擴大 Align Digital 平台的價值。這個機會不僅限於單獨的 Clear Aligner 或掃描器裝機。我們正將 iTero、掃描診斷、AI 驅動的治療規劃、Invisalign 治療、exocad 修復工作流程,以及診所應用程式串聯起來,為醫師與患者打造更整合的數位工作流程。這也代表超越傳統矯正領域的成長機會。透過牙科技工所,我們能更廣泛觸及一般牙醫,並促成將牙齒移動與修復治療及規劃整合的數位工作流程。
Invisalign Advanced Restorative Treatment, or ART, as we refer to, is a compelling example of Align's expanding its role in comprehensive dentistry, creating new clinical use cases, strengthening ecosystem connectivity and increasing our long-term opportunity across the broader dental marketplace. Importantly, this approach also aligns with the growing focus on oral health by helping clinicians plan treatment more holistically, recognizing the relationship between tooth position, function, restorative outcomes and long-term patient care. These growth opportunities reinforce one another, expanding our doctor-customer base, increasing utilization, addressing more patients and clinical needs, improving affordability and conversion and deepening adoption of our digital platform. So together, they give us multiple pathways to drive growth across Align.
我們所稱的 Invisalign 進階修復治療(Advanced Restorative Treatment,ART)就是一個極具說服力的例子,展現 Align 在全方位牙科領域中擴大角色:創造新的臨床使用情境、強化生態系連結,並提升我們在更廣泛牙科市場中的長期機會。重要的是,這種方法也符合口腔健康日益受到重視的趨勢,協助臨床醫師以更整體的方式規劃治療,認知牙齒位置、功能、修復結果與長期患者照護之間的關聯。這些成長機會彼此相互強化:擴大我們的醫師客戶基礎、提高利用率、服務更多患者與臨床需求、改善可負擔性與轉換率,並加深對我們數位平台的採用。因此,綜合而言,它們為我們在 Align 各面向推動成長提供多重路徑。
With that context, let me turn to our regional performance and the commercial priorities we're executing to drive growth. In the Americas, Clear Aligner shipments increased approximately 1.5% year-over-year, reflecting different performance trends across North America and Latin America. For the first time in six quarters, North America total orthodontic shipments increased year-over-year, supported by growth from DSOs. North American DSO shipments increased at double-digit rate overall, including growth across both orthodontists and GP customers.
在這樣的背景下,接下來我將談談各區域的表現,以及我們為推動成長所執行的商業優先事項。在美洲地區,Clear Aligner 出貨量年增約 1.5%,反映北美與拉丁美洲之間不同的表現趨勢。六個季度以來首次,北美矯正總出貨量年增,主要由 DSO 的成長所支撐。北美 DSO 出貨量整體以雙位數成長,包括矯正專科與一般牙醫客戶兩者皆有成長。
While the broader retail channel remains pressured, particularly for GP customers, orthodontist retail shipments improved sequentially in Q3 with teen orthodontist retail shipments also increasing year-over-year. We view the return to year-over-year orthodontist case growth, strong DSO performance and sequential improvements in orthodontic retail as an encouraging indicator, particularly given continued consumer softness. These early signs of improvement in North America reflect our focus on what we can control, strengthening commercial execution, sharpening our go-to-market strategies and deepening key partnerships to help drive conversion. Through sustained efforts to further this progress, we believe we can -- we will return North America back to growth.
雖然整體零售通路仍承受壓力,尤其是一般牙醫客戶,但第三季矯正專科的零售出貨量較前一季改善,且青少年矯正專科零售出貨量也年增。我們認為,矯正專科病例數恢復年增、DSO 表現強勁,以及矯正零售的連續改善,都是令人鼓舞的指標,特別是在消費者需求仍偏疲弱的情況下。北美這些初步改善跡象,反映我們專注於可控事項:強化商業執行、精準化我們的上市策略(go-to-market),並深化關鍵合作夥伴關係以推動轉換。透過持續努力以進一步推進這些進展,我們相信我們可以——我們將讓北美重回成長。
Our collaboration with HFD, Healthcare Finance Direct, integrates patient financing options into the Invisalign workflow to give patients greater payment flexibility and reduce administrative function for practices. We're seeing encouraging early traction with these offerings and are evaluating additional financing opportunities, including our new CareCredit pilot.
我們與 HFD(Healthcare Finance Direct)的合作,將患者融資選項整合進 Invisalign 工作流程,讓患者擁有更大的付款彈性,並降低診所的行政作業負擔。我們看到這些方案在早期已有令人鼓舞的進展,並正在評估其他融資機會,包括我們新的 CareCredit 試點計畫。
Patient interest in Invisalign remains strong, but affordability can be a barrier to starting treatment. These initiatives are part of our broader effort to address that barrier and convert more patient interest into treatment starts rather than waiting for consumer environment to improve. During the quarter, we launched the SHIFT Happens campaign to consumers to increase adult consumer awareness and Invisalign consideration. Our commercial focus is on helping practices convert that interest into consultation and treatment starts.
患者對 Invisalign 的興趣仍然強勁,但可負擔性可能成為開始治療的障礙。這些舉措是我們更廣泛努力的一部分,旨在解決該障礙,並將更多患者興趣轉化為實際啟動治療,而不是等待消費環境改善。本季度,我們面向消費者推出 SHIFT Happens 行銷活動,以提升成人消費者認知並增加對 Invisalign 的考量。我們的商業重點在於協助診所將這些興趣轉化為諮詢與治療啟動。
In Latin America, Clear Aligner growth remained strong across channels, was up double digits year-over-year. DSO shipments increased significantly year-over-year, while retail also grew, including positive performance across both GP dentists and orthodontists. Our Latin American priorities are centered on affordability and digital adoption, including expanding DSP availability, advancing Invisalign pay initiatives and broadening iTero access through additional partners, financing alternatives and scanner configurations.
在拉丁美洲,透明矯正器(Clear Aligner)在各通路的成長仍然強勁,年增率達雙位數。DSO 出貨量年增顯著,而零售通路亦成長,包括一般牙醫(GP)與矯正專科醫師皆呈現正向表現。我們在拉丁美洲的優先事項聚焦於可負擔性與數位化採用,包括擴大 DSP 的可用性、推進 Invisalign 付款方案(pay initiatives),並透過新增合作夥伴、融資替代方案與掃描器配置,擴大 iTero 的可及性。
Turning to EMEA. Clear Aligner shipments increased a double-digit growth rate year-over-year, supported by strong utilization across orthodontists and GP dentists and double-digit DSO growth. Retail was also an important contributor. EMEA retail shipments increased 8% year-over-year with growth across both orthodontists and GP dentist customers. In EMEA, we are focused on orthodontist utilization, teen and growing patient treatment and clinical education, especially Class II. We're working to expand the GP engagement through digital workflows and broader treatment opportunities, including ART. With DSOs, we continue to focus on improving conversion and scale adoption across practice locations. In Systems and Services, our focus is on expanding Lumina PC, targeting competitive and legacy iTero scanner users and expanding submitters through ART and third-party partnerships.
接著談 EMEA。透明矯正器出貨量年增達雙位數成長率,受惠於矯正專科醫師與一般牙醫的強勁使用率,以及 DSO 的雙位數成長。零售通路也是重要貢獻者。EMEA 零售出貨量年增 8%,矯正專科醫師與一般牙醫客戶皆有成長。在 EMEA,我們聚焦於提升矯正專科醫師使用率、青少年與成長中患者的治療,以及臨床教育,特別是第二類咬合(Class II)。我們正透過數位工作流程與更廣泛的治療機會(包括 ART)擴大一般牙醫的參與。針對 DSO,我們持續專注於提升轉化率並在各診所據點擴大採用規模。在系統與服務(Systems and Services)方面,我們的重點是擴大 Lumina PC,鎖定競品與既有 iTero 掃描器使用者,並透過 ART 與第三方合作夥伴擴大提交者(submitters)。
In APAC, Clear Aligner shipments were up double digits sequentially and increased year-over-year, driven by record doctor submitters and strong younger patient demand. Teen shipments increased double digits year-over-year led by China. Retail was the primary channel growth driver in APAC during Q3. APAC retail shipments increased 16% year-over-year with double-digit growth across both orthodontists and GP dentist customers. In APAC, we are focused on expanding adoption, improving conversion and strengthening the customer experience. This includes expanding private distributor coverage in China, increasing penetration in lower-tier cities and activating DSOs and accelerating tween and teen treatment. We're also focused on improving patient conversion in Japan through orthodontists growth programs as well as driving iTero initiatives.
在 APAC,透明矯正器出貨量較前一季呈雙位數成長,且年增,主要由創紀錄的醫師提交者數量與年輕患者的強勁需求所帶動。青少年出貨量年增達雙位數,由中國領先。Q3 期間,零售通路是 APAC 的主要成長驅動力。APAC 零售出貨量年增 16%,矯正專科醫師與一般牙醫客戶皆呈雙位數成長。在 APAC,我們聚焦於擴大採用、提升轉化率並強化客戶體驗。這包括在中國擴大民營經銷商覆蓋、提高在低線城市的滲透率、啟動 DSO,並加速 tween 與 teen 的治療。我們也專注於透過矯正專科醫師成長計畫提升日本的患者轉化,同時推動 iTero 相關舉措。
Across the rest of Asia, our focus is on building on the momentum in higher growth markets, including India, Korea and Taiwan. Customer experience is also an important growth lever across APAC. We're focused on clinical support, customer service, simplifying commercial processes and improving the digital experience. Together, these actions give us multiple avenues to expand growth across orthodontists, GP dentists, retail practices, DSOs, younger patients and digital workflows.
在亞洲其他地區,我們的重點是延續高成長市場的動能,包括印度、韓國與台灣。客戶體驗也是 APAC 的重要成長槓桿。我們聚焦於臨床支援、客戶服務、簡化商業流程並改善數位體驗。綜合而言,這些行動為我們提供多條途徑,以在矯正專科醫師、一般牙醫、零售診所、DSO、年輕患者與數位工作流程等面向擴大成長。
We continue to see a significant opportunity to expand the Invisalign adoption among GP dentists by connecting orthodontic treatment more closely with restorative and broader oral health care workflows. GP performance remains variable by market and channel. North America GP retail remains pressured, while EMEA and APAC GP Retail both delivered positive year-over-year growth and North America GP DSO grew double digits. These results reinforce our view that GP adoption can expand through clinical education, affordability, digital workflows and broader restorative treatment opportunities.
我們持續看到一個重大機會:透過將矯正治療更緊密地與修復治療及更廣泛的口腔健康照護工作流程連結,來擴大一般牙醫對 Invisalign 的採用。一般牙醫的表現仍因市場與通路而異。北美一般牙醫零售仍承壓,而 EMEA 與 APAC 的一般牙醫零售皆實現年增正成長,北美一般牙醫 DSO 則呈雙位數成長。這些結果強化了我們的觀點:一般牙醫的採用可透過臨床教育、可負擔性、數位工作流程以及更廣泛的修復治療機會來擴大。
ART is one example of how we are connecting alignment and restorative treatment planning. Along with iTero, exocad and our broader digital platform, these workflows help us engage GP dentists across a wider range of treatment options and create new opportunities to incorporate Invisalign into restorative patient care.
ART 是我們如何將矯正與修復治療規劃連結起來的一個例子。結合 iTero、exocad 以及我們更廣泛的數位平台,這些工作流程協助我們在更廣泛的治療選項中與一般牙醫互動,並創造將 Invisalign 納入修復患者照護的新機會。
Turning to Systems and Services. Q3 revenue was $175.5 million, down 7.6% year-over-year. The difference between reported revenue and underlying adoption remains important. This reflects a deliberate strategic shift toward flexible acquisition models rather than weakening demand. Revenue continues to reflect a greater mix of lower price configurations as well as flexible acquisition models, including leasing, financing, rentals and certified preowned systems.
接著談系統與服務(Systems and Services)。Q3 營收為 1.755 億美元,年減 7.6%。已報告營收與底層採用情況之間的差異仍然重要。這反映的是我們有意的策略性轉向:偏向更具彈性的取得模式,而非需求走弱。營收持續反映較低價格配置的占比提高,以及更具彈性的取得模式組合,包括租賃、融資、租用與認證二手機(certified preowned)系統。
The mix of iTero-leased units continues to grow and was up double digits again year-over-year. These customer-focused solutions are designed to lower the initial barrier to adoption, expand our customer footprint and give doctors more ways to access our digital technology. Our focus remains on expanding iTero's reach. And in Q3, the number of scanner units placed, including leased, rented and certified preowned systems increased double digits year-over-year to more than 157,000 systems globally. In limited pilot, 11 DSO location practices integrating iTero Lumina with Invisalign practice staff increased new patient exam capacity by approximately 15% without adding staff or extending operating hours.
iTero 租賃機台的組合占比持續提升,且年增再次達雙位數。這些以客戶為中心的解決方案旨在降低採用的初始門檻、擴大我們的客戶覆蓋面,並讓醫師有更多方式取得我們的數位技術。我們的重點仍是擴大 iTero 的觸及範圍。在 Q3,包含租賃、租用與認證二手機系統在內的掃描器投放台數年增達雙位數,全球系統數量超過 157,000 台。在有限試點中,11 個 DSO 據點診所將 iTero Lumina 與 Invisalign 診所人員整合後,在未增加人力或延長營業時間的情況下,新患者檢查容量約提升 15%。
Nearly 3/4 of participating locations improved productivity. The long-term value of Systems and Services extends beyond the initial scanner placement. A larger, more engaged and trained installed base creates opportunities to expand adoption of restorative workflows and generate reoccurring software and services revenue.
近 3/4 的參與據點提升了生產力。系統與服務的長期價值不僅止於初次掃描器投放。更大、更投入且受過訓練的裝機基礎(installed base)可創造機會,擴大修復工作流程的採用,並帶來經常性(reoccurring)的軟體與服務營收。
Before turning the call over to John, I want to briefly update you on our strategic initiatives we discussed last quarter. Following our constructive and ongoing discussions with Elliott Management, the first of our three independent directors joined Align Board in August. Quentin Blackford, President and CEO of iRhythm Technologies, is an accomplished global health care and med tech leader, and we're pleased to welcome him to Align.
在把電話會議交給 John 之前,我想簡要更新我們上季討論的策略性舉措。在我們與 Elliott Management 進行具建設性且持續的討論後,我們三位獨立董事中的第一位已於 8 月加入 Align 董事會。iRhythm Technologies 總裁兼執行長 Quentin Blackford 是一位卓越的全球醫療保健與醫療科技領導者,我們很高興歡迎他加入 Align。
Our strategic and operating model review is progressing with work focused on commercial effectiveness, organizational scalability, operating efficiency and resource allocation. We're particularly focused on ways to improve performance in North America, identifying additional margin expansion opportunities without compromising growth.
我們的策略與營運模式檢視正在推進中,工作重點聚焦於商業效能、組織可擴展性、營運效率與資源配置。我們特別專注於提升北美表現的方法,在不犧牲成長的前提下,找出額外的毛利率擴張機會。
We are incorporating early observations into our planning and operating process, and we'll provide additional detail as objectives are finalized and we can quantify their expected impact. The operating improvements we are already delivering also reflect broader work across manufacturing, productivity, automation, treatment efficiency and disciplined resource allocation. Our goal is straightforward: drive profitable growth while building a more efficient and scalable business.
我們正將初步觀察納入規劃與營運流程中,並將在目標定案且能量化其預期影響後,提供更多細節。我們已在交付的營運改善,也反映了製造、生產力、自動化、治療效率與嚴謹資源配置等更廣泛工作的成果。我們的目標很明確:在打造更高效率且更具可擴展性的業務之同時,推動獲利性成長。
With that, I'll turn the call over to John.
接下來,我把電話會議交給 John。
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
Thank you, Joe. Before turning to our results, I'd like to express my sincere gratitude for your leadership and partnership over the years as well as your many contributions to Align. Your impact will continue to benefit the company and help shape our future success. Total revenues for the third quarter were $1,014.8 million, up 1.9% year-over-year and in line with our Q3 expectations. On a constant currency basis, total revenue was 2.4% year-over-year.
謝謝你,Joe。在談到我們的業績之前,我想對你多年來的領導與合作,以及你對 Align 的諸多貢獻,致上誠摯的感謝。你的影響將持續使公司受益,並協助塑造我們未來的成功。第三季總營收為 10.148 億美元,年增 1.9%,符合我們對 Q3 的預期。以固定匯率計,總營收年增 2.4%。
Q3 Clear Aligner revenue was $839.3 million, up 4.2% year-over-year, primarily reflecting higher volume, price increases, lower net deferrals and higher non-case revenue, partially offset by geographic and product mix, higher discounts and unfavorable foreign exchange. On a constant currency basis, Q3 '26 Clear Aligner revenue was up 4.7% year-over-year.
Q3 透明矯正器營收為 8.393 億美元,年增 4.2%,主要反映出貨量增加、價格上調、淨遞延減少以及非病例(non-case)營收增加;部分被地理與產品組合、較高折扣及不利匯率所抵銷。以固定匯率計,Q3 '26 透明矯正器營收年增 4.7%。
Clear Aligner revenue per case shipment was $1,215, down 2.3% year-over-year or 1.8% at constant currency, consistent with our expectation, primarily due to mix shift to lower-priced countries and products and higher discounts, partially offset by price increases and lower net deferrals. Q3 Systems and Services revenue was $175.5 million, down 7.6% year-over-year. Revenue continued to reflect the mix towards lower-priced scanners and flexible acquisition models.
每病例出貨的透明矯正器(Clear Aligner)營收為 1,215 美元,年減 2.3%,或以固定匯率計年減 1.8%,符合我們的預期,主要係因產品組合轉向較低價格的國家與產品,以及折扣增加;部分被價格上調與淨遞延減少所抵銷。第三季系統與服務(Systems and Services)營收為 1.755 億美元,年減 7.6%。營收持續反映產品組合偏向較低價格的掃描器以及更具彈性的取得模式。
On a constant currency basis, Systems and Services revenue was down 7.1% year-over-year. Importantly, like-for-like scanner pricing stabilized during the quarter. Moving on to gross margin. Third quarter overall gross margin was 68.7%, up approximately 4.5 percentage points year-over-year or 5.3 percentage points at constant currency. Performance primarily reflected operational efficiencies and the absence of significant prior year charges, partially offset by lower ASP, restructuring and other charges and unfavorable foreign exchange.
以固定匯率計,系統與服務營收年減 7.1%。重要的是,同款(like-for-like)掃描器定價在本季趨於穩定。接下來談毛利率。第三季整體毛利率為 68.7%,年增約 4.5 個百分點,或以固定匯率計年增 5.3 個百分點。表現主要反映營運效率提升以及不再出現前一年重大費用,部分被較低 ASP、重整及其他費用與不利匯率所抵銷。
Importantly, the lower ASP is primarily due to product and geographic mix rather than change in pricing discipline. On a non-GAAP basis, Q3 gross margin was 70.4%, flat year-over-year and approximately 0.7 percentage points higher at constant currency, but modestly below our outlook of approximately 71%. The variance primarily reflected lower Clear Aligner ASP, product and geographic mix and Systems and Services mix, partially offset by manufacturing productivity, automation and lower refinement rates.
重要的是,較低的 ASP 主要來自產品與地理組合,而非定價紀律的改變。以非 GAAP 基礎計,第三季毛利率為 70.4%,與去年同期持平;以固定匯率計約高 0.7 個百分點,但略低於我們約 71% 的展望。差異主要反映透明矯正器 ASP 較低、產品與地理組合以及系統與服務組合,部分被製造生產力、自动化與較低的精修率(refinement rates)所抵銷。
Q3 Clear Aligner gross margin was 69.3%, up approximately 4.4 percentage points year-over-year, primarily reflecting operational efficiencies and lower depreciation expense on assets disposed of other than by sale, partially offset by elevated freight costs, restructuring costs and lower ASP. On a constant currency basis, Q3 Clear Aligner gross margin was up 5.2 percentage points year-over-year.
第三季透明矯正器毛利率為 69.3%,年增約 4.4 個百分點,主要反映營運效率提升以及對非出售方式處置資產的折舊費用下降,部分被較高的運費成本、重整成本與較低 ASP 所抵銷。以固定匯率計,第三季透明矯正器毛利率年增 5.2 個百分點。
Q3 Systems and Services gross margin was 66.2%, up approximately 4.9 percentage points year-over-year, primarily due to lower restructuring, COGS efficiencies and lower US tariff rates, partially offset by lower ASP. On a constant currency basis, Q3 Systems and Services gross margin was up 5.5 percentage points year-over-year. Third quarter operating income was $169.2 million, resulting in an operating margin of 16.7%, up approximately 7 percentage points year-over-year or 8.5 percentage points at constant currency. On a non-GAAP basis, Q3 operating margin was 24.4%, up approximately 0.5 percentage points year-over-year and approximately 1.4 percentage points at constant currency.
第三季系統與服務毛利率為 66.2%,年增約 4.9 個百分點,主要由於重整相關成本較低、銷貨成本(COGS)效率提升以及美國關稅稅率下降,部分被較低 ASP 所抵銷。以固定匯率計,第三季系統與服務毛利率年增 5.5 個百分點。第三季營業利益為 1.692 億美元,營業利益率為 16.7%,年增約 7 個百分點,或以固定匯率計年增 8.5 個百分點。以非 GAAP 基礎計,第三季營業利益率為 24.4%,年增約 0.5 個百分點,或以固定匯率計約增 1.4 個百分點。
Disciplined expense management and continued productivity improvements allowed us to exceed our non-GAAP operating margin expectation despite the modest gross margin shortfall. Our Q3 GAAP effective tax rate was 20.6% compared with 40.1% in the third quarter of 2025, primarily reflecting the prior year impact of restructuring charges in our jurisdictional mix of income and lower US taxes on foreign earnings in the current quarter. Our Q3 non-GAAP effective tax rate was 20%.
嚴謹的費用管理與持續的生產力改善,使我們即使毛利率略低於預期,仍能超越非 GAAP 營業利益率的預期。第三季 GAAP 有效稅率為 20.6%,相較於 2025 年第三季的 40.1%,主要反映前一年重整費用對各司法管轄區所得組合的影響,以及本季美國對海外收益課稅較低。第三季非 GAAP 有效稅率為 20%。
Third quarter diluted net income per share was $1.90, up $1.12 compared to the prior year. On a non-GAAP basis, Q3 diluted net income per share was $2.80, up 7.3% year-over-year. GAAP and non-GAAP EPS were unfavorably -- were each unfavorably impacted by approximately $0.24 year-over-year from foreign exchange.
第三季稀釋後每股淨利為 1.90 美元,較去年同期增加 1.12 美元。以非 GAAP 基礎計,第三季稀釋後每股淨利為 2.80 美元,年增 7.3%。GAAP 與非 GAAP EPS 均受到匯率因素不利影響——相較去年同期約減少 0.24 美元。
As of September 30, cash and cash equivalents totaled $1.145 billion, up approximately $140 million year-over-year. Cash flow from operations was $183.2 million, capital expenditures were $45.1 million and free cash flow was approximately $138 million. During Q3, we repurchased approximately 627,000 shares at an average price of $164.73 per share, returning $103.3 million to our shareholders. Year-to-date, we have repurchased $200 million of common stock. For fiscal 2026, we expect to repurchase approximately $500 million of common stock, up from $466 million repurchased in 2025 and reflecting the conviction of our Board and management in Align's long-term value.
截至 9 月 30 日,現金及約當現金合計 11.45 億美元,年增約 1.40 億美元。營運活動現金流為 1.832 億美元,資本支出為 4,510 萬美元,自由現金流約為 1.38 億美元。第三季期間,我們以每股平均 164.73 美元回購約 62.7 萬股,向股東返還 1.033 億美元。年初至今,我們已回購 2 億美元普通股。就 2026 會計年度而言,我們預期回購約 5 億美元普通股,高於 2025 年回購的 4.66 億美元,反映董事會與管理團隊對 Align 長期價值的信心。
Now turning to Q4 and fiscal 2026. I am pleased to deliver third quarter revenue and Clear Aligner volume in line with our outlook while improving year-over-year profitability. Consistent with our first and second quarters, these results were achieved against a challenging market backdrop as demand across the dental and orthodontic industry continued to be affected by a softer environment for discretionary health care spending and capital equipment investment.
接著談第四季與 2026 會計年度。我們很高興第三季營收與透明矯正器出貨量符合展望,同時年對年獲利能力提升。與第一季與第二季一致,這些成果是在具挑戰性的市場背景下達成,因牙科與齒顎矯正產業的需求持續受到非必需性醫療支出與資本設備投資環境轉弱的影響。
Those conditions persisted through the third quarter, and our fourth quarter outlook reflects what we continue to see across the broader market. Our updated 2026 guidance reflects a reduction in expected reported revenue versus our prior outlook provided at Q2, driven by two main factors. First, our Q4 Systems and Services revenues outlook is lower than our prior guidance. Although we expect scanner volume growth and solid scanner ASPs stabilize on a like-for-like basis during Q3, product mix continues to shift towards lower-priced scanners and more flexible acquisition models, which resonates well with customers amid a more challenging environment for capital equipment purchases. Second, we have slightly lowered our Clear Aligner volume as well as ASP assumption, largely driven by product and geographic mix in addition to foreign exchange.
上述情況延續至第三季,而我們對第四季的展望反映我們在更廣泛市場中持續觀察到的趨勢。我們更新的 2026 年指引,較先前在第二季提供的展望下調預期的報告營收,主要由兩項因素驅動。第一,我們對第四季系統與服務營收的展望低於先前指引。儘管我們預期掃描器出貨量成長,且同款(like-for-like)基礎下掃描器 ASP 在第三季趨於穩定,但產品組合仍持續轉向較低價格的掃描器與更具彈性的取得模式,這在資本設備採購環境更具挑戰之際更能引起客戶共鳴。第二,我們也小幅下調透明矯正器出貨量以及 ASP 假設,主要受產品與地理組合以及匯率影響。
Assuming no circumstances occur beyond our control that could impact our business, for Q4 2026, we expect worldwide revenues to be in the range of $1 billion to $1.020 billion. We expect Q4 Clear Aligner volume to be up low single digits year-over-year. We expect Clear Aligner ASP to be down approximately 1% year-over-year. We expect Systems and Services revenue to be in the range of $170 million to $180 million. We expect worldwide GAAP gross margin to be approximately 71% and non-GAAP gross margin to be approximately 72%.
在假設不發生任何超出我們控制、可能影響業務的情況下,對於 2026 年第四季,我們預期全球營收介於 10.0 億至 10.20 億美元。我們預期第四季透明矯正器出貨量年增低個位數。我們預期透明矯正器 ASP 年減約 1%。我們預期系統與服務營收介於 1.70 億至 1.80 億美元。我們預期全球 GAAP 毛利率約為 71%,非 GAAP 毛利率約為 72%。
We expect GAAP operating margin to be approximately 20%. We expect non-GAAP operating margin to be approximately 26%. For Q4 2026, we expect to repurchase up to $300 million of our common stock. For fiscal 2026, we expect 2026 worldwide revenue to be approximately $4.11 billion to $4.13 billion. We continue to expect 2026 Clear Aligner volume and revenue growth to be up approximately 5% to 6% year-over-year.
我們預期 GAAP 營業利益率約為 20%。我們預期非 GAAP 營業利益率約為 26%。對於 2026 年第四季,我們預期最多回購 3 億美元普通股。就 2026 會計年度而言,我們預期 2026 年全球營收約為 41.1 億至 41.3 億美元。我們仍預期 2026 年透明矯正器出貨量與營收成長年增約 5% 至 6%。
We expect 2026 Clear Aligner ASP to be slightly below 2025. We expect 2026 Systems and Services revenue to be $715 million to $725 million. We expect 2026 GAAP operating margin to be approximately 16.2%, up approximately 2.7 points year-over-year. We expect 2026 non-GAAP operating margin of approximately 23.7%, representing approximately 100 basis point improvement year-over-year, consistent with our previous guidance. We expect capital expenditures of approximately $125 million to $150 million.
我們預期 2026 年透明矯正器 ASP 將略低於 2025 年。我們預期 2026 年系統與服務營收為 7.15 億至 7.25 億美元。我們預期 2026 年 GAAP 營業利益率約為 16.2%,年增約 2.7 個百分點。我們預期 2026 年非 GAAP 營業利益率約為 23.7%,代表年對年約改善 100 個基點,與我們先前指引一致。我們預期資本支出約為 1.25 億至 1.50 億美元。
We expect to repurchase approximately $500 million of our common stock during 2026. As we look to 2027, we believe we are well positioned to deliver another year of revenue growth and margin expansion. Importantly, our preliminary planning assumes an operating environment broadly consistent with current conditions and does not require a consumer recovery. We expect to continue driving Invisalign volume growth in 2027, record doctor submitters, improving utilization and the growth initiatives discussed today support that confidence with additional initiatives under development. We also continue to expect a broadly stable Clear Aligner pricing environment with ASP slightly down, driven primarily by product and geographic mix.
我們預期在 2026 年回購約 5 億美元的本公司普通股。展望 2027 年,我們相信公司已具備良好條件,可再實現一年營收成長與利潤率擴張。重要的是,我們的初步規劃假設營運環境大致與目前狀況一致,且不需要消費者復甦。我們預期 2027 年將持續推動 Invisalign 出貨量成長、創下醫師提交數新高並提升使用率;今天討論的成長計畫以及正在開發的其他計畫,支持我們的信心。我們也仍預期透明矯正器的定價環境整體維持穩定,ASP 略為下滑,主要由產品與地理組合所驅動。
For Systems and Services, 2026 has been a transition year for revenue. We expect solid unit growth and continued expansion of our installed base and we expect stable ASPs positioning Systems and Services for revenue growth in 2027. On profitability, we continue to target at least another 100 basis points of non-GAAP operating margin improvement in 2027, building on the approximately 100 basis points we expect to deliver in 2026. Our focus is on improving efficiency while preserving investment in the initiatives that support sustainable revenue growth. Share repurchases should provide an additional benefit to earnings per share growth as we continue to view buybacks as an attractive use of capital at prices that we do not believe reflect Align's long-term value creation potential.
就系統與服務而言,2026 年是營收的過渡年。我們預期單位數量將穩健成長、裝機基礎持續擴大,且 ASP 維持穩定,使系統與服務在 2027 年具備營收成長動能。在獲利能力方面,我們仍以 2027 年非 GAAP 營業利益率至少再改善 100 個基點為目標,並以我們預期 2026 年可達成約 100 個基點的改善為基礎。我們的重點是在提升效率的同時,保留對支持可持續營收成長之計畫的投資。在我們認為股價未能反映 Align 長期價值創造潛力的水準下,我們仍將回購視為具吸引力的資本運用方式;股票回購亦可為每股盈餘成長帶來額外助益。
We will provide our full 2027 outlook when we report fourth quarter results following the completion of our strategic and operating model review with Jen leading the business. With that, I'll turn it back to Joe. Joe?
在 Jen 領導業務、且我們完成策略與營運模式檢視後,於公布第四季財報時,我們將提供完整的 2027 年展望。接下來我把時間交還給 Joe。Joe?
Joseph Hogan - Chief Executive Officer, President, Director
Joseph Hogan - Chief Executive Officer, President, Director
Thanks, John. Let me close by bringing together what you've heard today. We delivered solid Q3 performance with record third quarter Clear Aligner shipments, record doctor submitters, improved utilization, continued expansion of iTero customer footprint and stronger operating performance, varied by market and channel. But we also saw important areas of traction, including overall orthodontist growth, strong DSO performance in Latin America, broad-based growth in EMEA and strong retail performance in APAC and America.
謝謝,John。讓我在結尾把大家今天聽到的重點整合一下。我們第三季表現穩健:第三季透明矯正器出貨量創新高、醫師提交數創新高、使用率提升、iTero 客戶覆蓋面持續擴大,且營運表現更強;不過各市場與通路的表現有所差異。但我們也看到一些重要的進展,包括整體矯正專科醫師成長、拉丁美洲 DSO 表現強勁、EMEA 廣泛成長,以及 APAC 與美洲零售表現強勁。
While the external environment remains challenging, our results continue to demonstrate that we have meaningful opportunities to improve performance through execution regardless of the pace of the macroeconomic recovery. We're focusing on increasing utilization among orthodontists, expanding Invisalign, adoption among GP dentists, growing with DSOs and strategic accounts, extending our leadership in kids and teens, improving affordability and patient conversion and increasing adoption of our digital workflows.
儘管外部環境仍具挑戰,我們的結果持續顯示:無論總體經濟復甦速度如何,我們都能透過執行力找到顯著的改善機會。我們正聚焦於提升矯正專科醫師的使用率、擴大一般牙醫對 Invisalign 的採用、與 DSOs 及策略性客戶共同成長、延伸我們在兒童與青少年領域的領導地位、提升可負擔性與病患轉換率,以及提高數位工作流程的採用。
Across Systems and Services, our priorities are to expand the iTero customer footprint, increased utilization and connect scanning more deeply with diagnostics, treatment planning, restorative workflows and Invisalign treatment across the Align digital platform. We also have a significant innovation pipeline ahead of us. Across digital treatment planning, AI-enabled capabilities, growing patient treatment, restorative workflows, scanning solutions and CAD/CAM software, we're investing in technologies that can expand clinical applicability, improve the customer experience and make our business more productive at scale. We continue to be excited about our next-generation direct fab for patient 3D printed materials platform, what we call NXT Technology.
在系統與服務方面,我們的優先事項是擴大 iTero 客戶覆蓋面、提升使用率,並在 Align 數位平台上,將掃描更深度地與診斷、治療規劃、修復工作流程以及 Invisalign 治療連結。我們也擁有相當可觀的創新管線。在數位治療規劃、AI 賦能能力、提升病患治療量、修復工作流程、掃描解決方案與 CAD/CAM 軟體等方面,我們正投資可擴大臨床適用性、改善客戶體驗,並讓業務在規模化下更具生產力的技術。我們對下一代用於病患 3D 列印材料平台的直接製造(direct fab)技術仍感到振奮,我們稱之為 NXT Technology。
NXT unlocks greater control, consistency and precision across appliance. Design enables an entirely new level of Invisalign performance and personalization. Building on the Invisalign Palatal Expander, our first direct 3D-printed orthodontic appliance, we are broadening the application of 3D printing across the Invisalign portfolio as well as expanding it into new categories. Invisalign Specifix attachment systems launched this year expands our 3D-printing capabilities beyond aligners and appliances into attachment system itself. By conducting digital treatment planning, manufacturing, clinical delivery, it represents another step toward a fully integrated digital workflow.
NXT 可在各類矯治裝置上帶來更高的控制力、一致性與精準度。其設計使 Invisalign 的效能與個人化達到全新層級。在 Invisalign Palatal Expander(我們第一款直接 3D 列印的矯正裝置)的基礎上,我們正擴大 3D 列印在 Invisalign 產品組合中的應用,並延伸至新的品類。今年推出的 Invisalign Specifix 附著系統,將我們的 3D 列印能力從矯正器與裝置,延伸到附著系統本身。透過進行數位治療規劃、製造與臨床交付,這代表我們朝向完全整合的數位工作流程再邁進一步。
This week, we will begin a US pilot of a new product category, sports mouthguards, powered by our 3D printing technology and material science capabilities. Sports mouthguards represent a large and growing market opportunity and then growing awareness of concussion risk in contact sports. There is also a significant overlap with kids and teens as we expect it to drive awareness and utilization of Invisalign treatment through Invisalign doctors while providing incremental revenues. Invisalign Sports Guard, is a custom direct 3D-printed sports mouthguard made from an iTero digital scan.
本週,我們將在美國啟動一項新產品類別的試點:運動護齒套(sports mouthguards),由我們的 3D 列印技術與材料科學能力所驅動。運動護齒套代表一個龐大且持續成長的市場機會,並且隨著對接觸性運動腦震盪風險的認知提升而成長。此外,該產品與兒童及青少年族群也有顯著重疊;我們預期它可透過 Invisalign 醫師提升對 Invisalign 治療的認知與使用,同時帶來增量營收。Invisalign Sports Guard 是一款客製化、直接 3D 列印的運動護齒套,使用 iTero 數位掃描製作。
It comes in multiple thickness options and will be available through participating Invisalign providers. Invisalign Sports Guards are customizable for each athlete's unique needs for comfort and sport, optimized for high performance specific to the activity, thanks to the power of high-performance polymers and unique 3D-printed designs, expected to offer over time a broader set of diagnostics and other sensing capabilities. These are important steps in a broader road map and includes additional orthodontic applications and the opportunity to apply direct fabrication technology more broadly to aligner treatment. We will continue to advance the road map as we scale the technology and validate each application. What gives me confidence looking ahead is that we are not dependent on any single growth driver, geography or customer segment.
它提供多種厚度選項,並將透過參與的 Invisalign 供應醫師提供。Invisalign Sports Guards 可依每位運動員在舒適度與運動需求上的獨特需求進行客製化,並藉由高性能聚合物與獨特的 3D 列印設計之力,針對特定活動最佳化高效能;且預期隨時間推進,可提供更廣泛的診斷與其他感測能力。這些是更廣泛路線圖中的重要步驟,並包含更多矯正應用,以及將直接製造技術更廣泛應用於隱形矯正治療的機會。隨著我們擴大技術規模並驗證各項應用,我們將持續推進該路線圖。讓我對未來有信心的是:我們不依賴任何單一成長驅動因素、地理區域或客戶區隔。
We have opportunities to increase orthodontist utilization, expand GP adoption, grow with DSOs, extend our leadership in kids and teens, improve affordability and patient conversion and increased adoption of the Align Digital platform. Before we open the call for questions, I want to briefly address my decision to step down and the Planned CEO Succession announcement we made today. Leading Align has been a tremendous privilege and this is an amazing decision -- a meaningful and amazing decision for me as we move forward. The process has been carefully planned for some time. It reflects a thoughtful long-term focus.
我們有機會提升矯正專科醫師使用率、擴大一般牙醫採用、與 DSOs 共同成長、延伸我們在兒童與青少年領域的領導地位、提升可負擔性與病患轉換率,並提高 Align 數位平台的採用。在我們開放提問之前,我想簡要說明我決定卸任,以及我們今天發布的「計畫性 CEO 接班」公告。能夠領導 Align 是莫大的榮幸;在我們向前邁進之際,這對我而言是一個重大的決定——一個有意義且令人振奮的決定。這個流程已經審慎規劃了一段時間。它反映了深思熟慮的長期聚焦。
As announced, our Board has appointed Jennifer Davis as Align's next CEO. Jen will join us on November 2 as CEO-elect and a member of our Board. She will assume the CEO and President role on December 31 of this year. Jen brings 33 years of leadership experience, including leading Procter & Gamble's global health care business, with global experience across innovation, digital transformation, brand building operations and customer development and oral health. Jen will be joining the company with powerful innovation platform, a talented global team, trusted relationship with doctors around the world and significant opportunities across orthodontics and digital dentistry.
如同公告所述,我們的董事會已任命 Jennifer Davis 為 Align 下一任 CEO。Jen 將於 11 月 2 日加入我們,擔任候任 CEO(CEO-elect)並成為董事會成員。她將於今年 12 月 31 日接任 CEO 與總裁職務。Jen 擁有 33 年的領導經驗,包括領導寶僑(Procter & Gamble)全球健康照護事業;並在創新、數位轉型、品牌打造、營運與客戶開發以及口腔健康等領域具備全球經驗。Jen 加入公司時,我們已具備強大的創新平台、優秀的全球團隊、與全球醫師之間的信任關係,以及在矯正與數位牙科領域的重大機會。
I'm extremely proud of Align, the strong foundation we've established and the relentless contributions of every member of our Board, management team and organization. I am confident in this transition plan, and I'm looking forward to working closely with Jen over the coming months. I strongly believe she is the right leader to build on that foundation and lead Align through the next phase of growth and value creation. My focus remains squarely on driving the business, executing the priorities we discussed today and continue to advance the growth, innovation and operating initiatives underway across Align. I remain confident in the opportunities ahead for Align and the team executing our strategy and in our ability to continue to build long-term value for our customers, shareholders and employees.
我為 Align 感到無比自豪,為我們建立的堅實基礎,以及董事會、管理團隊與組織中每一位成員不懈的貢獻感到驕傲。我對這項交接計畫充滿信心,並期待在未來幾個月與 Jen 密切合作。我堅信她是合適的領導者,能在此基礎上再接再厲,帶領 Align 進入下一階段的成長與價值創造。我的重心仍將專注於推動業務、落實我們今天討論的優先事項,並持續推進 Align 全面展開的成長、創新與營運計畫。我仍對 Align 未來的機會、對團隊執行我們策略的能力,以及我們持續為客戶、股東與員工創造長期價值的能力充滿信心。
Thank you for joining us. Operator, we'll now open for questions.
感謝各位參與。接線員,我們現在開放提問。
Operator
Operator
(Operator Instructions) Michael Cherny, Leerink Partners.
(接線員指示) Michael Cherny,Leerink Partners。
Michael Cherny - Equity Analyst
Michael Cherny - Equity Analyst
Joe, best of luck in retirement as you move on. I'll just ask one now. I'm sure there's plenty of others. But as you think about the changing conditions that you saw underlying the difference in views, in particular on case starts between what you saw in 3Q versus what you saw in 4Q, can you give us a sense on what some of the factors were relative to the low single-digit case start expectations? What are you seeing from a leading indicator perspective? Anything else you can point to in terms of the drivers and the build on the 4Q numbers? The 3Q level was very strong across the Board. Curious what you're seeing relative to how the setup is for 4Q, though, as you look to -- into next year?
Joe,祝你退休後一切順利、邁向下一段旅程。我先問一個問題。我相信還有很多其他問題。但當你回想你所看到、導致觀點差異的環境變化時,特別是你在3Q看到的病例啟動(case starts)與4Q看到的之間差異,你能否讓我們了解一下,相對於「低個位數」病例啟動預期,背後有哪些因素?從領先指標的角度,你看到了什麼?還有沒有其他你能指出的驅動因素,以及4Q數字上修(build)的原因?3Q的水準在各方面都非常強勁。但我很好奇,當你展望4Q、並看向明年時,你對整體布局(setup)的觀察是什麼?
Joseph Hogan - Chief Executive Officer, President, Director
Joseph Hogan - Chief Executive Officer, President, Director
Yes. Thanks, Michael. We felt great about our third quarter performance. We see a challenged market really across the globe in so many countries. And as I mentioned in the script and John mentioned in his script, too, we felt really good about being able to deliver in that kind of environment.
是的。謝謝你,Michael。我們對第三季的表現感到非常滿意。我們看到全球許多國家都面臨具挑戰性的市場環境。正如我在講稿中提到、John在他的講稿中也提到,我們對能在那樣的環境下交出成果感到非常有信心。
As we look at the fourth quarter, we see continued challenged consumer overall. And that's a common theme we see across the Board. I mean, obviously, with our Systems and Services business, we have a reorientation that you saw in the third quarter and you've seen this year, and that's reflected in our go-forward statement, too. So this is not a singular type of variable that we're discussing here. This is a broad-based, I think, reticent consumer that we sense not just in North America, but different parts of the world, and that's being reflected in our guidance.
展望第四季,我們看到整體消費者仍然承壓。而這是我們在各方面都看到的共同主題。我的意思是,顯然在我們的系統與服務(Systems and Services)業務上,你在第三季以及今年都看到我們的重新調整(reorientation),而這也反映在我們對未來的表述中。所以我們討論的並不是單一變數。我認為這是一種廣泛性的、偏保守(reticent)的消費者心態;我們不只在北美感受到,在世界不同地區也同樣如此,而這也反映在我們的指引中。
Operator
Operator
Jon Block, Stifel.
Jon Block,Stifel。
Jonathan Block - Analyst
Jonathan Block - Analyst
Joe, I'll start with a question that's likely for you and probably Jennifer as well. The sports mouthguard, I know it's a bit early, but more importantly, just big picture, what does this say about Align? Like is this the start of going into adjacencies? You called out mouthguards before -- when you first got there, we heard about sleep apnea. Is this a Clear Aligner company going forward? Is this a 3D-printing company going forward? We would just love your thoughts there.
Joe,我先從一個可能是問你、也可能是問Jennifer的問題開始。關於運動護齒套(sports mouthguard),我知道現在談可能還有點早,但更重要的是,從大方向來看,這對Align意味著什麼?這是否代表開始進入相鄰領域(adjacencies)?你之前提過護齒套——你剛上任時,我們也聽到你談到睡眠呼吸中止症(sleep apnea)。未來這會是一家透明牙套(Clear Aligner)公司嗎?未來這會是一家3D列印公司嗎?我們很想聽聽你的想法。
Joseph Hogan - Chief Executive Officer, President, Director
Joseph Hogan - Chief Executive Officer, President, Director
Jon, great question. Look, when I started, obviously, sleep apnea was on the table and I shot that because I felt the technology was diversionary. I thought it was a channel we didn't understand overall. A reimbursement system, we had not a prayer of understanding and being able to sell in front of a customer. And it was also an item that is very difficult to be able to manufacture and do it in scale like we have to do.
Jon,問得很好。你看,我剛開始時,睡眠呼吸中止症確實在討論範圍內,但我把它否決了,因為我覺得那項技術會分散焦點。我認為那是一個我們整體並不理解的通路。報銷/給付(reimbursement)體系,我們根本不可能理解,更不用說能在客戶面前銷售。而且那也是一個非常難以製造的產品,要像我們必須的那樣規模化生產更是困難。
And so I just thought it was a diversion in the sense of what the company would focus on. If I look at mouthguard, Jon, I can tell you that almost every orthodontist we have out there is asking for mouthguards. They feel that's a leader product for them in that teen market, especially with schools and different kind of demand profiles with schools and kids in those specific ZIP codes. The reason I wanted -- I thought it was time to do this is we have a unique resin we've developed. It has significant advantages over resins that are used for mouthguards today.
所以我認為那會分散公司應該聚焦的方向。但如果看護齒套,Jon,我可以告訴你,我們幾乎每一位矯正醫師(orthodontist)都在詢問護齒套。他們覺得那是他們在青少年市場的主打產品,尤其是與學校相關、以及不同學校與孩子在特定郵遞區號(ZIP codes)下的需求型態。我之所以想做——我覺得現在是時候做——是因為我們開發出一種獨特的樹脂。相較於目前護齒套使用的樹脂,它有顯著優勢。
It's 3D printed. So the first mouthguard that you can make specifically for certain sports, certain configurations in the way people speak and how they present themselves. It gives you a huge amount of flexibility in the sense of how you can go after that marketplace. Sports mouthguard business is anywhere between $6 billion to $8 billion and how you look at it. It's primarily a boil and bite kind of a marketplace.
它是3D列印的。因此,這是第一款可以針對特定運動、特定配置,以及人們說話方式與外觀呈現來量身打造的護齒套。這讓你在切入市場時具備非常大的彈性。運動護齒套市場規模大約在60億到80億美元之間,取決於你怎麼看。它主要是一個「煮沸後咬合成型」(boil and bite)的市場。
It means non-exact kind of manufacturing science that's used about it. So Jon, why in this case, unique technology, very unique from a consumer standpoint, right in line with our channels of distribution, right? Our orthos want to have it. GPs want it too, but orthos also. So we can sell it through our current channels without any kind of friction. So I look at it as 180 degrees versus sleep apnea devices.
也就是說,它並不是一種精密製造科學(non-exact manufacturing science)的產品。所以Jon,在這個案例中,我們有獨特技術,從消費者角度也非常獨特,而且完全符合我們的分銷通路,對吧?我們的矯正醫師想要它。一般牙醫(GPs)也想要,但矯正醫師也同樣需要。因此我們可以透過現有通路銷售,幾乎沒有任何摩擦。所以我認為這與睡眠呼吸中止症裝置是180度相反的情況。
Jonathan Block - Analyst
Jonathan Block - Analyst
Great color. And then as a follow-up, John, for the quarter, like case is better, I think, certainly better and better than feared. ASP light, maybe you can give a little bit more on that dynamic because -- and I'm thinking about this correctly, comp no AA is not an upfront ASP hit arguably. And then maybe you could just also touch on the exit rate. I know most of the revisions for 4Q were around Systems and Services and maybe a little FX. But it does seem like you noodled down Clear Aligner a bit. So maybe you can just talk about that exit rate there.
很有幫助的補充。接著追問,John,就本季而言,病例數(case)表現更好,我想確實更好、也比市場擔心的要好。ASP偏弱,你或許可以多談談這個動態,因為——如果我理解正確的話,comp no AA 可能不算是前端ASP的直接衝擊。另外你也能否談談退出率(exit rate)?我知道4Q的大部分修正主要在系統與服務(Systems and Services),以及可能有一點匯率(FX)。但看起來你們也把透明牙套(Clear Aligner)稍微下修了一些。所以也請你談談那邊的退出率。
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
Yes. Thanks, Jon. I'll start with ASP. Yes, ASPs were above what we expected. We had a little bit of unfavorable FX. We get the continued country and product mix. So two of the reasons driving some of that ASP kind of sequentially down, really the growth that you see in many of these markets that just have a lower list price. So you see India and China and others that are sequentially and year-over-year growing. That shows up from an ASP standpoint as well as introducing DSP and some of that touch-up cases that we have. We do see that.
好的,謝謝你,Jon。我先從ASP開始。是的,ASP高於我們的預期。我們有一點不利的匯率(FX)。同時也有持續的國家與產品組合(mix)影響。所以,這兩個因素導致ASP在環比上有些下滑;實際上你看到的成長,來自許多名目定價(list price)較低的市場。因此你會看到印度、中國以及其他市場在環比與同比都在成長。這會反映在ASP上;另外我們也導入DSP以及一些補做(touch-up)病例。我們確實看到這些影響。
It's just a low list price product that ends up showing up in ASP, but it was able to help us in the end, drive volume, as we said, and ultimately, deliver the margin that we needed. And that's how we look at that. I would say when we think about the exit rate and we're factoring in, in our guidance what we saw in Q3, we factor in what we see in October. And that's what we used to inform our guide. So no change in terms of how we do it or what we look at. It's just a reflection of a continued challenging market and things that we're doing to try to help offset it.
這些產品的名目定價較低,最後會在ASP上顯現出來,但它最終能幫助我們推動量的成長,如我們所說,並且最終交出我們需要的毛利率。我們就是這樣看待的。至於退出率(exit rate),以及我們在指引中納入的因素:我們會把Q3看到的情況納入,也會把10月看到的情況納入。這就是我們用來形成指引的依據。所以在我們的做法或觀察重點上沒有改變。這只是反映市場持續具挑戰性,以及我們為了嘗試抵消影響所採取的措施。
Operator
Operator
Brandon Vazquez, William Blair.
Brandon Vazquez,William Blair。
Brandon Vazquez - Analyst
Brandon Vazquez - Analyst
Joe, congrats on a great career at Align and good luck on the next steps. I wanted to focus first, let's just kind of double-click on the macro a little bit. I think the prior two were asking something similar to this. But can you talk a little bit more granular about what have things incrementally from Q2 to Q3 on the macro side? Are there any pockets of things getting worse or better?
Joe,恭喜你在Align有一段很棒的職涯,也祝你接下來一切順利。我想先聚焦在宏觀環境,稍微再深入一點。我想前兩位也在問類似的問題。但你能否更細緻地談談,從Q2到Q3,在宏觀面有哪些增量變化?是否有任何區塊變得更差或更好?
Joe, I think you had said North America declined in the quarter in your prepared remarks. Did I hear that correctly? And is that -- again, is that better or worse? We don't always get figures like that. So just curious if you can kind of level set us on relative to last quarter, how some of the key geographies are doing?
Joe,我想你在事先準備的發言中提到北美在本季下滑。我聽得對嗎?而那是——再問一次——算是更好還是更差?我們不一定總能拿到那樣的數字。所以想請你幫我們校準一下:相較於上一季,一些關鍵地理區域的表現如何?
Joseph Hogan - Chief Executive Officer, President, Director
Joseph Hogan - Chief Executive Officer, President, Director
Brandon, good question. On -- I'll just start with the US where you started with two in North America. I mean we felt good about Latin America and our performance there was great. I was happy to see that we had positive orthodontic growth for the first time in -- I think it's the six quarters that we've had in the US, which is really positive.
Brandon,問得好。就——我先從你提到的美國開始,你一開始提到北美有兩點。我的意思是,我們對拉丁美洲的表現感到樂觀,而且我們在那裡的表現非常出色。我很高興看到我們在美國的矯正業務首次出現正成長——我想這是我們在美國連續六個季度以來第一次,這非常正面。
On the GP side, obviously, we saw continued erosion. That's a larger bucket of doctors we have to call on. There's challenges across keeping up with those doctors and pushing those doctors, the consumers that we talked about, being a little less reticent, especially in that GP channel to convert. So I feel -- as I mentioned in the script, too, I feel good about our ability to really push on the GP side. You see our DSO business there continues to grow.
在GP端,顯然我們看到持續的侵蝕。那是一個更大的醫師群體,我們必須去拜訪。在跟進這些醫師並推動這些醫師方面存在挑戰;我們談到的消費者也比較不那麼願意,尤其是在GP通路上轉化。所以我覺得——正如我在講稿中也提到的——我對我們真正加大推進GP端的能力感到有信心。你也看到我們的DSO業務在那裡持續成長。
It's that retail segment that's challenging, in particular GPs that are doing less than 10 cases a year. And so -- but I feel we've arranged our workforce properly to be able to go after that. We have good early warning signals right now. We're -- we might be losing GPs in different places that we can move our sales force in that way. So I see a challenged market, a challenged consumer, but I feel good about our product base, and I feel good about our ability to address it.
真正具挑戰的是零售細分市場,特別是每年做不到10個案例的GP。所以——但我覺得我們已經把人力配置得很到位,能夠去攻這一塊。我們目前有很好的早期預警訊號。我們——我們可能在不同地區流失GP,而我們可以用那種方式調整我們的銷售團隊部署。所以我看到的是一個充滿挑戰的市場、充滿挑戰的消費者,但我對我們的產品基礎有信心,也對我們解決問題的能力有信心。
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
The products that are really starting to take hold. We talked a lot about the NO AA or reduced amount of AA type products. They're growing and across the globe, growing at a triple-digit rate, which is great. That's really helping win with doctors, especially in that gray area with that upfront cost. And then we also talked a lot about, and we're seeing more and more, especially in this challenged environment where those potential patients are turning to financing to be able to help them afford that treatment. And you see our partnerships with many finance companies, not just in North America, but it's really now become more across the globe, and that's helping win those gray areas as well with those patients.
那些產品真的開始站穩腳跟了。我們談了很多NO AA或減少AA量這類產品。它們正在成長,而且在全球以三位數的成長率成長,這很棒。這確實有助於贏得醫師,特別是在前期成本那個灰色地帶。然後我們也談了很多,而且我們看到越來越多——尤其在這種充滿挑戰的環境下——那些潛在患者轉向融資,以協助他們負擔得起治療。你也看到我們與許多金融公司的合作夥伴關係,不僅在北美,現在其實已擴展到全球,這也有助於在患者端贏下那些灰色地帶。
Brandon Vazquez - Analyst
Brandon Vazquez - Analyst
Got it. And then intra-quarter, we had gotten a lot of questions around China VBP. I know there's some nuances to your exposure to China and then the private versus the public. I don't -- hopefully, I didn't miss something in the prepared remarks, but maybe a good opportunity to kind of level set investors what the potential exposure is to China VBP in the orthodontic side? And then also what kind of is the latest and expectations of timing?
了解。然後在季度內,我們收到很多關於中國VBP的問題。我知道你們在中國的曝險有一些細節,以及私立與公立之分。我不——希望我沒有漏掉你們在事先準備的發言中提到的內容,但也許這是個好機會,幫投資人重新校準一下:在矯正端,中國VBP可能帶來的曝險是什麼?另外,最新進展與時間點預期是什麼?
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
Yes, Brandon, this is John. So VBP will participate in. It's going through its process. I would expect that as things open up into the fourth quarter in terms of products that will be entered into, we'll participate in. As you know, it's been well documented, it usually starts on the public side.
是的,Brandon,我是John。所以我們會參與VBP。它正在走流程。我預期隨著第四季在可納入的產品方面逐步開放,我們會參與。如你所知,這已經有很多公開資料記載,通常是先從公立端開始。
We don't have a lot of exposure on the public side. Only about 15% of our business in China is public. Most of it's private. But we'll participate in that. We think that it helps grow in this market where like we said, from a company standpoint, most of our product is on the private side.
我們在公立端的曝險不大。我們在中國的業務只有大約15%是在公立端。大多數是在私立端。但我們會參與其中。我們認為這有助於在這個市場成長;正如我們所說,從公司角度來看,我們的大部分產品是在私立端。
But the vast majority of cases done in China are done with wires and brackets. So if VBP allows more exposure, more people to be able to use Clear Aligners, that will help participate and help drive. We feel that with our operations there, our treatment planning, the sales force, everything that we have on a go-to-market standpoint really will help us as we navigate through that process.
但在中國,絕大多數的病例仍是用鋼絲與托槽完成。所以如果VBP能讓更多人有機會使用透明牙套(Clear Aligners),那將有助於參與並帶動成長。我們認為,憑藉我們在當地的營運、治療規劃、銷售團隊,以及我們在市場進入(go-to-market)方面的一切配置,確實能在我們推進這個流程時提供很大幫助。
Operator
Operator
Vik Chopra, BMO Capital Markets.
Vik Chopra,BMO Capital Markets。
Vikramjeet Chopra - Equity Analyst
Vikramjeet Chopra - Equity Analyst
Joe, best of luck to you and thanks for all your help over the past several years. The question for me is on 2027 framework that you laid out. You've targeted another 100 basis points of margin improvement without a consumer recovery. Can you talk about the biggest drivers of that? Is this a floor or a base case? And does the Elliott operating review, is there potential for that to add to that?
Joe,祝你一切順利,也感謝你在過去幾年提供的所有協助。我想問的是你提出的2027年框架。你們在沒有消費者復甦的情況下,仍目標再提升100個基點的利潤率。能否談談最大的驅動因素是什麼?這是底線情境還是基本情境?另外,Elliott的營運檢視是否有可能在此基礎上再加分?
Joseph Hogan - Chief Executive Officer, President, Director
Joseph Hogan - Chief Executive Officer, President, Director
John?
John?
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
Yes. I can start with that, Vik. We have a lot of productivity and efficiency programs in place. Obviously, we know how to manufacture and manufacture at scale there to drive productivity. So many of the actions that we've been doing for the last several years are coming to fruition, and we're driving that improved productivity.
是的,Vik,我可以先回答。我們已經推行許多生產力與效率提升計畫。顯然,我們知道如何製造,並且能以規模化製造來帶動生產力。所以我們過去幾年所做的許多行動正在開花結果,並推動生產力提升。
We're seeing that this year. We see the gross margin improvements that we've had in the business. Some of it's product related, where you have that less dependence on these complicated products that have multiple refinements and we go to fewer refinement-type products. That drives a lot of productivity in our business. So some of it's at the product level, some of it's at the initiatives that we have to be able to help drive improvements in productivity.
我們今年就看到了。我們看到業務的毛利率改善。其中一部分與產品有關:我們降低對那些需要多次精修(refinements)的複雜產品的依賴,轉向較少精修類型的產品。這會在我們的業務中帶來大量的生產力提升。所以一部分是在產品層面,一部分是在我們為推動生產力改善而採取的各項措施層面。
Of course, we're going through this strategic review and understanding where we could save money, where we could invest to be able to drive growth and do it in a profitable way. So we feel good about the efforts that we have up until this point. We'll continue to make refinements to it. And then at the end of Q4 here, we'll be prepared to talk about what that means for 2027. But we hold to the fact that the op margin improvement next year that we've committed to that at least 100 basis point improvement is progressing well, and we'll update more about what that means for the rest of the P&L next quarter.
當然,我們正在進行這項策略檢視,了解哪些地方可以省錢、哪些地方可以投資以推動成長,並以獲利的方式來做。所以我們對截至目前的努力感到有信心。我們會持續做微調。然後在這裡的第四季末,我們會準備好談這對2027年意味著什麼。但我們仍堅持:我們已承諾明年的營業利益率至少改善100個基點,這項進展良好;我們也會在下個季度更新這對損益表其餘部分的意涵。
Operator
Operator
Jeff Johnson, Baird.
Jeff Johnson,Baird。
Jeffrey Johnson - Senior Research Analyst
Jeffrey Johnson - Senior Research Analyst
Joe, again, I'll just add the congrats on a great career and good luck in retirement. Let me ask one follow-up question on VBP, if I could, and then I want to ask a case volume question as well. But John, on VBP, obviously, a lot of moving parts, as you said, maybe getting bigger into the public side if you bid on that side of the business here in this round. On the private side, we are hearing the Chinese government kind of pushing for private docs to also participate from a pricing perspective in VBP. I guess net, we don't know how that's going to play out. But should VBP be a good guy, a bad guy for you guys next year, there's all the moving parts on what happens in your private market pricing versus if you get public market incremental volumes. So help us out maybe on just net how we should think about this?
Joe,我再一次補一句,恭喜你有個很棒的職涯,也祝你退休生活順利。如果可以的話,我想先追問一個關於VBP的問題,然後我也想問一個關於案例量(case volume)的问题。不過John,關於VBP,正如你所說,顯然有很多變動因素;如果你們在這一輪對公立端的業務投標,可能會更深入公立端。在私立端,我們聽到中國政府似乎也在推動私立醫師在定價層面參與VBP。我想整體而言,我們還不確定會如何發展。但就明年而言,VBP對你們會是好事還是壞事?因為變動因素很多:私立市場的定價會怎麼走,以及如果你們拿到公立市場的增量量能。所以能否幫我們釐清一下,整體上應該怎麼看待這件事?
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
Well, as you're right, there are a lot of moving pieces to it, Jeff. And I think when you look at it as -- if it gets it will get to private as it goes to private. The real question will become is what doctors do with those price differences, do they pass them on to the potential patients? We hope they do because that will drive an increased amount of utilization and adoption of Clear Aligners. So we hope that that's where it ends up going.
嗯,你說得對,Jeff,這裡面確實有很多變動因素。我想當你把它看作——如果它會延伸到私立端,那就會在它延伸到私立端時發生。真正的問題會變成:醫師如何處理那些價差,他們會把價差轉嫁(或讓利)給潛在患者嗎?我們希望他們會,因為那將推動透明牙套(Clear Aligners)的使用量與採用率提升。所以我們希望最後會朝那個方向發展。
But we see increased volume that will come through. That's typically what happens to VBP. We think we're properly positioned in China to be able to kind of in China for China to be able to manage the cost. And I think when you look at it overall from a net-net revenue standpoint, it's -- to us, it's neutral to positive, just from the standpoint, you're going to drive a lot of volume, I think, as it works its way through the system. And you will have some price, but I think the volume helps offset it. And as long as that product portfolio that we have is in place as well as some of the in-China operations we have, we think we're properly positioned.
但我們確實看到將會帶來的量在增加。這通常就是VBP會發生的情況。我們認為我們在中國的佈局是到位的,能夠以「在中國、為中國」的方式來管理成本。而且我認為,若從整體淨淨收入(net-net revenue)的角度來看,對我們而言是中性到正面,因為隨著它在系統中逐步推進,我認為你會帶動很大的量。你會面臨一些價格壓力,但我認為量的提升有助於抵消。只要我們現有的產品組合到位,再加上我們在中國的一些在地營運,我們認為我們的定位是恰當的。
Jeffrey Johnson - Senior Research Analyst
Jeffrey Johnson - Senior Research Analyst
All right. Fair enough. And then just on the case volume side, you're guiding low single digits for 4Q. I think when I think about how you guided '26 previously on last quarter's call and guided 3Q on the 2Q call, it feels like that 4Q case volume guidance globally is maybe down 1 point or 2 relative to what you were thinking. Just taking your pulse on that, is that about right, maybe 1 point or 2 lighter than you would have been expecting, number 1. And you'll hit very similar comps. You hit a 7-plus comp here in the fourth quarter. The next few comps into '27 are going to be similar. Is that kind of low single digit for 4Q against a 7-plus comp about the way we should think about coming up against those other 7% comps through the first few quarters of next year as well?
好。可以理解。那再談一下病例量(case volume)方面,你們對第四季(4Q)的指引是低個位數成長。我想,當我回想你們上季電話會議先前對'26的指引,以及在2Q電話會議對3Q的指引,感覺你們這次對4Q全球病例量的指引,可能比你們原先的想法低了1到2個百分點。想請教一下我的理解是否正確:第一,是否大概就是比你們原本預期輕了1到2個百分點。而且你們將面對非常相近的比較基期(comps)。你們在第四季的比較基期是7%以上。接下來進入'27的幾個季度,比較基期也會類似。那麼,對於第四季在7%以上比較基期下仍是低個位數成長,我們是否也應該用同樣的方式來看待明年初幾個季度面對其他約7%比較基期的情況?
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
You're right from a stack standpoint. The stack is very similar to the two-year stack that we've seen at Q3 and then kind of the implied guidance for Q4. So you get to that, Jeff. I think what you see is continued consumer that's challenged across many markets. You've got to do a lot of things to try to motivate them to go into treatment when they have that challenge, financing some of the product portfolio and other things that we're trying to do to help with the go-to-market efforts.
從堆疊(stack)的角度來看你說得對。兩年期的堆疊與我們在Q3看到的,以及對Q4的隱含指引非常相似。所以你會得到那個結論,Jeff。我認為你看到的是,許多市場的消費者仍持續承壓。在他們面臨這種挑戰時,你必須做很多事情來激勵他們進入治療,包括為部分產品組合提供融資,以及我們正在嘗試做的其他事情,以協助市場推進(go-to-market)工作。
So slight tweaks that we've made based on what we're seeing on a global basis. But in that overall revenue that we're talking about for the year of that 5% to 6% and similar amount from a volume standpoint for Clear Aligners. So overall, that hasn't changed too much from a total year standpoint, but just adjusting slightly for Q4.
因此,我們根據全球層面所看到的情況做了一些小幅調整。但就我們今年所談的整體營收5%到6%成長,以及Clear Aligners在量的角度也有相近幅度而言。所以從全年總體來看並沒有太大改變,只是對第四季做了些微調整。
Operator
Operator
Elizabeth Anderson, Evercore ISI.
Elizabeth Anderson,Evercore ISI。
Elizabeth Anderson - Analyst
Elizabeth Anderson - Analyst
Congratulations, Joe, on your retirement. I wanted to dig in a little bit on the scanner side. I mean if we think about the implied scanner guide, it's a little bit lower, I think, than expectations, but also to Jeff's just point now, the comps get a lot tougher. So I guess, how do we think about it kind of lapping last year's upgrade sales? You talked about the lower price scanner mix, softer leasing, some of the capital leasing that you sort of offer. Like I guess, could you help us double-click on some of those different components so we can sort of understand the lay of the landscape for that demand environment and sort of how to think about that going forward?
Joe,恭喜你退休。我想在掃描儀(scanner)方面再深入一點。我的意思是,如果我們看隱含的掃描儀指引,我認為它比預期略低一些;但也呼應Jeff剛才的點,比較基期會變得更艱難。所以我想問的是,我們該如何看待它在今年升級銷售(upgrade sales)之後的「跨越比較基期」(lapping)?你提到較低價格的掃描儀產品組合(mix)、較疲弱的租賃(leasing),以及你們提供的一些資本租賃(capital leasing)。能否請你協助我們更細緻地拆解這些不同組成,讓我們能理解該需求環境的全貌,以及未來該如何看待?
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
Yes. That's a good question, Elizabeth. This is John. So first and foremost, the scanner equipment sales that we have, the unit volume has been very strong. We see the installed base up double digit. So we're getting good adoption of our scanners, and we're very pleased with that. That's a great scanner, great portfolio. We have been able to get to those doctors. Some still want to have the latest and greatest Lumina. All the bells and whistles are great, and that comes through as equipment sell-through.
好的。這是個好問題,Elizabeth。我是John。首先也是最重要的,我們的掃描儀設備銷售,單位出貨量(unit volume)一直非常強勁。我們看到裝機基數(installed base)以雙位數成長。因此我們的掃描儀採用率(adoption)表現良好,我們對此非常滿意。這是一款很棒的掃描儀,也是一個很好的產品組合。我們也成功觸及到那些醫師。有些人仍然想要最新、最強的Lumina。所有的附加功能都很棒,而這會反映在設備的銷售出貨(sell-through)上。
Some doctors are like, I don't need the full system, I'll do more of a flex model where they just hook into the laptop and it fits their needs. Some doctors are looking at maybe the certified preowned. Any which way they want those units, we're happy to sell, just whatever fits their needs. The added component that we see is a lot more leasing, a lot more rental. And those doctors are like, we just -- we want the scanner. I just don't want to pay for it up front. So we're seeing those placements happening, you're starting to build up more of that rental income because it's from previous quarter rental revenue that's from previous quarters that's now building up into whatever current quarter you're in as well as leasing and so on. So that's an evolution that continues to happen within the business.
有些醫師會覺得,我不需要完整系統;我會採用更彈性的模式,只要接到筆電上就能符合需求。有些醫師可能會考慮認證二手機(certified preowned)。不管他們想用哪種方式取得這些設備,我們都樂於銷售,只要符合他們的需求即可。我們看到的另一個新增面向是更多的租賃、更多的租用(rental)。那些醫師會說,我們就是想要掃描儀。我只是不想一次付清。因此我們看到這些布建(placements)正在發生,你也開始累積更多租用收入,因為它是來自前幾季的租用營收,會在你所處的當季持續累積,並且也包含租賃等。所以這是業務中持續發生的一種演進。
What we saw as we went from second quarter to third quarter, we saw relatively stable pricing on an overall equipment standpoint. So that was a good sign for us that it's kind of more bottomed out there from a price standpoint, and we feel good that we can build off of that for Q4. And more importantly, as we look into 2027, we build off of that to '27 such that we expect Systems and Services to grow next year because the pricing has stabilized, because of the trade-offs that are happening between equipment sale and leasing so that when we look at 2027, it's much more stable. And as we've said in the past, as we've talked about, you get about the same growth between the equipment side of our business as well as the Clear Aligner side, and that's what our expectation would be for next year.
我們看到從第二季到第三季,整體設備面向的定價相對穩定。這對我們而言是個好跡象,代表價格面大致已在那裡觸底,我們也有信心在第四季以此為基礎繼續推進。更重要的是,當我們展望2027年,我們也會以此為基礎走向'27,因此我們預期明年Systems and Services會成長,因為定價已經穩定,也因為設備銷售與租賃之間正在發生取捨(trade-offs),使得我們看2027年時會更穩定。而且如同我們過去所說、也討論過的,你會看到我們設備端業務與Clear Aligner端業務大致有相近的成長,而這就是我們對明年的預期。
Elizabeth Anderson - Analyst
Elizabeth Anderson - Analyst
And then if we think about that scanner growth and you talked about the switch to leasing, we've obviously historically seen a really nice attach rate of the case growth to those scanner sales. Are you seeing anything different in the attach rate in terms of new cases from one of those placements or leases or secondhand sales as what we've seen historically versus sort of when you just had the prior model of just new sort of sales?
那如果我們思考掃描儀的成長、以及你提到轉向租賃,我們過去一直看到病例成長與掃描儀銷售之間有很不錯的帶動率(attach rate)。你們是否看到帶動率有任何不同:也就是,來自這些布建、租賃或二手銷售所帶來的新病例,與過去歷史上相比是否有差異;相較於先前主要以全新銷售為主的模式?
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
Yes, what you see is you see doctors who might not have wanted to go and use our scanner. What we see, we talked about a record number of submitters that we have in the quarter. Some of that is helping by being able to get a scanner that they might not have gone to before. The acquisition cost is less because they're leasing it. It's just this monthly fee that they pay.
是的,你會看到一些醫師可能原本不想去使用我們的掃描儀。我們看到的是,我們提到本季有創紀錄的提交者(submitters)數量。其中一部分的助力來自於:我們能讓他們取得一台掃描儀,而這在以前他們可能不會去採用。因為他們用租賃方式取得,獲客成本(acquisition cost)更低。他們只需要支付每月費用。
And then it starts the front end of the digital ecosystem. They're starting to use Invisalign and digitize so that it helps them grow their business in a digital orthodontic way. So we like the combination of being able to help them digitize their practice and really be as efficient and beneficial for their patients as possible.
接著它就啟動了數位生態系的前端。他們開始使用Invisalign並進行數位化,從而以數位矯正的方式幫助他們拓展業務。因此我們喜歡這種組合:一方面協助他們將診所數位化,另一方面也讓他們能盡可能以最高效率、對病患最有利的方式提供服務。
Operator
Operator
Jason Bednar, Piper Sandler.
Jason Bednar,Piper Sandler。
Jason Bednar - Analyst
Jason Bednar - Analyst
Joe, I'll just echo the congrats there and pleasure working with you over the past several years. Guys, I do appreciate the color here on 2027, the framework there. Maybe I want to layer on to some of the questions earlier. I know this business can be tough to predict at times, but you are throwing out some initial guardrails or floors, whatever you want to call them. What are the macro assumptions you're embedding in that Aligner outlook? Is it more or less status quo for the US and international? And then can you get a little bit more detailed? We've been poking around at some of the different moving parts. But just on the ASP outlook, what are the puts and takes that are contributing to the 2027 framework?
Joe,我也想在此再次致上祝賀,並且很高興在過去幾年能與你共事。各位,我確實很感謝你們在 2027 年、以及相關框架上提供的補充說明。也許我想在先前的一些問題上再加問幾點。我知道這個業務有時很難預測,但你們提出了一些初步的護欄或底線,不管你們想怎麼稱呼。你們在那個 Aligner 展望中所內嵌的總體經濟假設是什麼?對美國與國際市場而言,是否大致維持現狀?另外能否再更具體一些?我們一直在研究一些不同的變動因素。但就 ASP(平均售價)展望而言,哪些拉抬與壓抑因素共同促成了 2027 的框架?
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
Yes. When we look at 2027 framework, first off, we're not expecting much of a change in the overall consumer. The consumer will be what it does. It's a challenging environment for inflation and other inputs that those potential patients have. So we're not expecting really a change from that.
是的。當我們看 2027 的框架時,首先,我們不預期整體消費者端會有太大變化。消費者會呈現它本來的樣子。在通膨以及其他投入成本等因素下,對那些潛在患者而言是個具挑戰的環境。所以我們確實不預期那方面會有什麼改變。
What we are pushing and helping drive is how do we go to market with various products and combinations to be able to get to our doctors to be able to help them start cases, ultimately do more cases? You couple that with financing to those potential patients, really trying to get those reluctant patients to actually get into treatment. So that's how we're building throughout this year in this challenging environment and what we would expect for next year. As we think about our growth and what we've seen from a growth this year and our expectation for next year is, look, you're going to see some of those markets where we've had great growth on the international side. I would expect those to continue.
我們正在推動並協助帶動的是:我們如何以各種產品與組合進入市場,讓我們能觸及醫師,協助他們啟動病例,最終做更多病例?再搭配對那些潛在患者的融資方案,真正試著讓那些猶豫的患者實際進入治療。因此,這就是我們在今年這個具挑戰的環境中所建立的做法,以及我們對明年的預期。當我們思考成長、以及今年看到的成長與對明年的預期時,坦白說,你會看到一些我們在國際市場端成長很好的市場。我預期那些會持續下去。
India and China and Latin America and others, they're going to continue. Those are great growth opportunities for us. That continues. They come at a lower list price. It's just what the market is. You're also going to see some of these products like the DSP, touch-up cases and so on. That will end up -- we end up growing faster, too. Those two combinations, geographic plus product mix, take our ASPs down. And what we've been seeing is that 1% to 2%. This year, it will be down about 1%. But I think from a planning standpoint to that geographic and product mix of about 1% to 2%.
印度、中國、拉丁美洲以及其他市場都會持續。那些對我們而言是很好的成長機會。這會延續下去。但它們的定價表列價格較低。市場就是如此。你也會看到一些產品,例如 DSP、補救(touch-up)病例等等。這些最終也會讓我們成長更快。這兩個組合——地理區域加上產品組合——會把我們的 ASP 拉低。而我們看到的幅度大約是 1% 到 2%。今年大約會下降 1%。但我認為從規劃角度來看,考量地理與產品組合,大約抓 1% 到 2% 是合理的。
Jason Bednar - Analyst
Jason Bednar - Analyst
Okay. That's helpful. And maybe I'll follow up just on scanners and services to follow up on Elizabeth's question previously. Where does the confidence come from the '26 here will be the bottom and that the shift to the alternate purchasing model won't gain further momentum as we move into next year. I guess just wondering where the confidence lies that this isn't some secular shift that you won't see, again, play out again next year.
好的。這很有幫助。另外我想就掃描器與服務追問一下,延續先前 Elizabeth 的問題。你們的信心來源是什麼,認為 2026 年會是谷底,且隨著我們進入明年,轉向替代性採購模式不會再進一步加速?我想問的是,你們的信心在哪裡,認為這不是某種結構性(長期)轉變,不會在明年再次上演?
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
Yes. Think about it, Jason, we've got -- from a new product standpoint, we've certainly seen some of that price shifting. And we started seeing this in the first quarter really played out in the second quarter. It was stable in the third quarter, meaning that pricing was about equal and this is really across the globe. So what we also see is strong demand. And there's demand for this product. That installed base growing like it is. The product is well received. All the products that we have are well received. It's just that.
是的。Jason,你想想看——從新產品的角度,我們確實看到一些價格的轉移。我們在第一季開始看到,並在第二季真正反映出來。第三季則趨於穩定,也就是說定價大致相當,而且這其實是全球範圍。我們同時也看到強勁需求。這個產品是有需求的。裝機基礎以目前的速度成長。產品的市場反應很好。我們所有產品的市場反應都很好。就是這樣。
In some cases, it's at a lower price, but we think that's stabilized. And then when you look at the leasing and rental, some markets have shifted to that. It is in all markets, but in some markets, it shifted to that. And what you do is you just forgo as much -- you don't get as much revenue upfront, but you get that revenue later on. The key for us is we want those doctors to be able to have that scanner at their practice, help them digitize and lead to more use of digital orthodontics. And we think that's a good thing. And we're expecting to build on that as we go into 2027.
在某些情況下價格較低,但我們認為那已經穩定下來。再來看租賃與出租(rental),有些市場已經轉向那種模式。並非所有市場都如此,但有些市場確實轉向那樣。你所做的取捨是:你放棄一部分——也就是你拿不到那麼多的前期收入,但你會在之後取得那筆收入。對我們而言關鍵是,我們希望那些醫師能在診所裡配備那台掃描器,協助他們數位化,並帶動更多數位矯正的使用。我們認為那是好事。而且我們預期在邁向 2027 年時,會在此基礎上繼續推進。
Operator
Operator
Steven Valiquette, Mizuho Securities.
Steven Valiquette,Mizuho Securities。
Steven Valiquette - Equity Analyst
Steven Valiquette - Equity Analyst
Let me also offer my congrats to Joe on 11-plus years of successful leadership at Align. I guess just for me, again, not to ask too many questions on 2027 overall on this call, but the comment again about expecting to continue to drive Invisalign volume growth in 2027. I know it's kind of intentionally vague so we have a preliminary view and we left wide open to interpretation. So I guess I don't know if there's a further message within that. I'm just trying to confirm, maybe yes or no, is there anything structurally that -- right now that would prevent the growth in 2027 being similar to the mid-single digits you have in 2026? Without stating the obvious, something like 5% to 10% growth would be phenomenal, but 1% growth while its growth would not be viewed great right now relative to expectations and consensus, et cetera. So hopefully, that question makes sense.
我也想向 Joe 在 Align 超過 11 年的成功領導致上祝賀。就我而言,同樣地,我不想在這通電話上對 2027 整體問太多問題,但你們再次提到預期在 2027 年持續推動 Invisalign 的量(volume)成長。我知道這可能是刻意保持模糊,因為我們目前只是初步觀點,也保留了很大的解讀空間。所以我想我不確定其中是否還有更進一步的訊息。我只是想確認一下,可能用是或否回答:就目前而言,有沒有任何結構性的因素會阻止 2027 年的成長與 2026 年的中個位數成長相近?不必說得太明白,像 5% 到 10% 的成長會非常出色,但 1% 的成長雖然也是成長,然而相對於目前的預期與市場共識等,可能就不會被視為理想。希望這個問題表達得清楚。
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
Look, I think -- Steve, this is John. So when you think of what we're trying to do is, we're expecting a challenging macro environment. I don't know if it magically gets better into next year. So given that the work that we're doing from the product portfolio and what we're doing to go to market as well as some of that consumer and other financing options to be able to help with those potential patients to go into treatment. It served us well this year.
我想——Steve,我是 John。當你思考我們正在做的事情時,我們預期總體環境仍具挑戰。我不確定到了明年經濟是否會神奇地變好。因此,基於我們在產品組合、上市策略(go-to-market),以及一些面向消費者與其他融資選項上的工作,來協助那些潛在患者進入治療。這些在今年對我們很有幫助。
When we think about our Clear Aligner revenue and volume, as we talked about for the full year, that 5% to 6%, that's served us well in 2026. We'll give more details about what it means for 2027 in light of all the efforts that we have going on. But we feel good about what we're trying to do to try to drive that utilization and adoption go-to-market because the underlying overall market hasn't changed. The vast majority of cases are still done with wires and brackets. And we have the opportunity to grow in this space. It's just that macro that we have to work against, and that's why we want to make sure that we can continue to grow.
當我們看 Clear Aligner 的營收與量(volume)時,如同我們對全年所談到的 5% 到 6%,這在 2026 年對我們也很有幫助。我們會在考量所有正在進行的努力之下,提供更多關於 2027 年意涵的細節。但我們對於自己想做的事情感到樂觀:透過上市策略推動使用率與採用率,因為底層的整體市場並沒有改變。絕大多數病例仍然是用鋼絲與托槽完成。而我們在這個領域有成長機會。只是我們必須在這樣的總體環境下努力,因此我們要確保能持續成長。
Joseph Hogan - Chief Executive Officer, President, Director
Joseph Hogan - Chief Executive Officer, President, Director
Yes, I think what I want to emphasize, too, and just over John's comments is because there's a lot of questions about 2027, we're not predicting 2027 is going to fall off in some way. Just like John said, we expect very -- we can't predict what the economy is going to look like. We feel good about our ability to execute in a difficult situation from a consumer standpoint, and we'll continue to execute that way.
是的,我也想強調一點,並在 John 的評論之上補充:因為大家對 2027 有很多疑問,我們並不是在預測 2027 會以某種方式下滑。就像 John 說的,我們——我們無法預測經濟會是什麼樣子。我們對自己在消費者端處於困難情況下的執行能力感到有信心,而且我們會持續以同樣方式執行。
Operator
Operator
Erin Wright, Morgan Stanley.
Erin Wright,摩根士丹利。
Erin Wright - Equity Analyst
Erin Wright - Equity Analyst
Congrats, Joe, again. It was great working with you. You mentioned financing a few times now. And I guess, can you speak to some of the newer financing initiatives in terms of where that stands in terms of the rollout of those? And just anything that you can give us in terms of how that's translating into conversion?
Joe,再次恭喜你。很高興能與你合作。你已經提到融資好幾次了。我想請你談談一些較新的融資計畫,目前推行進度如何?以及你能否分享一下,這些措施如何轉化為轉換率的提升?
And then just a second question, just on macro and the pressures that you're seeing. Like what are you seeing in terms of also like share shift back to brackets and wires or something like that? Or is it just purely underlying kind of demand trend and who's walking in the front door?
第二個問題是關於總體環境以及你們看到的壓力。例如,你們是否看到市占回流到傳統矯正器(brackets)與鋼絲(wires)之類的情況?還是說這純粹是底層需求趨勢,以及走進診所的客群結構所致?
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
John Morici - Chief Financial Officer, Executive Vice President - Global Finance
Maybe I could start with some of the financing. We're seeing many countries and many regions adopting financing, using external financing that really haven't done it before. And we're helping lead the way and do it in a way where we're working with some of these financing companies being able to get them into those offices through our sales team, being able to talk about the financing options. More and more in this environment, people are looking for ways to be able to afford things. And that gets ultimately down to a month-by-month basis.
也許我可以先從融資談起。我們看到許多國家與地區開始採用融資、使用外部融資,而這些地方過去其實並沒有這樣做。我們正在協助引領方向,並以一種方式來推動:我們與部分融資公司合作,透過我們的銷售團隊把他們帶進這些診所,讓他們能夠介紹融資選項。在目前這樣的環境下,越來越多人在尋找能負擔得起的方式。而這最終會落到按月付款的層面。
So I would say, Erin, you're seeing this much broader across the US, and it's helping us win those gray areas with those potential patients. And what I'm really encouraged about is we're solving some of these in Europe that we never really thought we could get through. These finance companies are now much more willing to partner with us and be partners with us to be able to help provide financing solutions to consumers. So it's early that we're seeing this, but it's good progress. And we feel good about this as being a differentiator to help, especially in this economy to be able to upgrow the business.
所以我會說,Erin,你會看到這在美國更廣泛地發生,並且幫助我們在那些「灰色地帶」的潛在患者中勝出。而讓我真正感到鼓舞的是,我們正在解決一些在歐洲過去從未想過能突破的問題。這些融資公司現在更願意與我們合作、成為夥伴,來協助提供消費者融資解決方案。我們目前看到的仍屬早期,但進展良好。我們也對此作為差異化優勢感到有信心,尤其在這樣的經濟環境下,有助於推動業務成長。
Joseph Hogan - Chief Executive Officer, President, Director
Joseph Hogan - Chief Executive Officer, President, Director
And in your second part of your question, Erin, about wires and brackets and how we're doing. Remember, majority of the cases we do are adults still. From a team standpoint, we -- you hear more and more about wires and brackets and different things. But as I mentioned in my script, we really feel good about the early intervention that we have. When you look at Invisalign First, you look at IPE, Mandibular Advancements, those products are growing at double digits for us right now.
至於你問題的第二部分,Erin,關於鋼絲與矯正器以及我們的表現。請記得,我們做的大多數病例仍然是成人。從團隊角度來看——你會越來越常聽到鋼絲、矯正器以及各種不同的方案。但如我在講稿中提到的,我們對早期介入的布局非常有信心。當你看 Invisalign First、看 IPE、看 Mandibular Advancements,這些產品目前對我們而言都以雙位數成長。
And it gives us really good access into that teen and tween marketplace overall. So we'll keep pushing those products, and we'll keep driving adults, too. And that's -- our shift happens piece is aimed right at that to help the orthodontics grow their adult side and then also with the GP side also. So I feel good about our go-to-market, both in product and also from a marketing standpoint.
這也讓我們能更好地切入整體青少年與學齡前後(tween)市場。因此我們會持續推動這些產品,同時也會持續推動成人市場。而這——我們的「shift happens」策略正是針對這一點,協助矯正專科擴大其成人端業務,同時也涵蓋一般牙科(GP)端。所以我對我們的 go-to-market 策略很有信心,無論是產品面或行銷面。
Operator
Operator
Kevin Caliendo, UBS.
Kevin Caliendo,瑞銀。
Kevin Caliendo - Analyst
Kevin Caliendo - Analyst
Joe, good luck with everything going forward in case our paths don't cross again. I wanted to talk about the mouthguard a little bit because it's certainly interesting. Is this a product that do you anticipate distributing through like a retail channel? Meaning are you going to go to DICK'S Sporting Goods and see an Align mouthguard? Or is it a mouthguard that's going to be specific for people that might be going through the orthodontists already or GP?
Joe,祝你接下來一切順利,如果我們之後沒有再碰面。我想聊一下護齒套(mouthguard),因為這確實很有意思。你們是否預期會透過零售通路來銷售這個產品?也就是說,你會在 DICK'S Sporting Goods 看到一個 Align 的護齒套嗎?還是這會是針對已經在矯正專科或一般牙科(GP)治療中的人所提供的護齒套?
Like where is the end user going to learn about these mouthguards? And I guess the pricing strategy here, is this like a premium product versus a generic product because it doesn't sound like generic if you have some kind of resin that's proprietary. And I guess my concern is, if you sell it somewhere that's not in a retail setting, does it potentially impact the retainer business because I'm guessing the pricing of a retainer might be a lot more than a mouthguard. But I'd just love to hear a little bit about the strategy and more about the mouthguard.
終端使用者會從哪裡得知這些護齒套?另外在定價策略上,這會是高端產品、還是一般通用產品?因為如果你們有某種專有樹脂,聽起來就不像是一般產品。我還有個疑慮:如果你們不是在零售通路販售,是否可能影響維持器(retainer)業務?因為我猜維持器的價格可能遠高於護齒套。但我很想多聽聽你們的策略,以及更多關於護齒套的細節。
Joseph Hogan - Chief Executive Officer, President, Director
Joseph Hogan - Chief Executive Officer, President, Director
Yes, Kevin, it's a good question. First of all, we won't be selling it directly to consumers. That's not the game. We have the channels that we want to work it through with orthodontists really asking for this product line because of their strong teen marketplace, and they know parents are very concerned in that way. And we think our GP channel will do it, too.
是的,Kevin,這是個好問題。首先,我們不會直接賣給消費者。那不是我們的玩法。我們會透過我們想合作的通路來推進;矯正專科其實一直在要求這條產品線,因為他們在青少年市場很強,也知道家長在這方面非常在意。我們認為一般牙科(GP)通路也會推動。
So we will keep with our channel strategy and not go outside that from an OEM standpoint. It is a premium product overall. When you look at it from a retainer standpoint, it won't hurt the retainer business at all because it's just completely different functionality overall. It is very unique, as I mentioned. It's really the only truly 3D-printed mouthguard that we know with this kind of unique resin.
因此我們會維持既有的通路策略,從 OEM 的角度不會跨出這個範圍。整體而言,這是一個高端產品。從維持器的角度來看,它完全不會傷害維持器業務,因為功能性完全不同。如我提到的,它非常獨特。就我們所知,這基本上是唯一真正以 3D 列印製作、並使用這種獨特樹脂的護齒套。
And we have a lot of, obviously, design flexibility in order to make it as comfortable and as functional as we possibly can for athletes. And we like the idea that they can kind of design the mouthguard that they want, and we'll stay within those protective procedures for that particular sport. So I see this as just right in line with our channel strategy. It's right in line with our technical strategy with 3D printing. It's a big opportunity for us overall.
而且我們在設計上有很大的彈性,能讓它對運動員而言盡可能舒適、也盡可能具備功能性。我們也喜歡這樣的概念:他們可以某種程度上設計自己想要的護齒套,而我們會在該運動項目的防護規範內進行。所以我認為這完全符合我們的通路策略。也完全符合我們以 3D 列印為核心的技術策略。這對我們整體而言是一個很大的機會。
Kevin Caliendo - Analyst
Kevin Caliendo - Analyst
If I can ask a quick follow-up. I've got some soccer and hockey and football parents asking me to ask, is this something that you can strap on to a helmet because they always get locked and chewed upon?
我可以快速追問一下嗎?有一些踢足球、打冰球和美式足球的家長請我代問:這是否能加一條帶子固定在頭盔上?因為護齒套常常會被咬住、卡住。
Joseph Hogan - Chief Executive Officer, President, Director
Joseph Hogan - Chief Executive Officer, President, Director
Kevin, I have two answers to that. One is we can 3D print that, we can make it any way you want to. So if you want to have a strap on it that snaps, so we could do that. But secondly, we plan to make these things so comfortable that kids aren't going to take them out of their mouth.
Kevin,這個問題我有兩個回答。第一,我們可以用 3D 列印做到,我們可以依你想要的方式製作。所以如果你想要一條可扣上的帶子,我們可以做。但第二,我們計畫把它做得非常舒適,讓孩子不會把它從嘴裡拿出來。
A lot of time, what our research basically is they take it out because they can't speak. Often, they can't swallow properly and they have to pull that out, they lose them on their helmet. So that's again why we like this technology. We can design this in a different way because it is a higher-performance resin and a much more capable design criteria than what you could go with boil and bite and form and fill kind of mouthguards now.
很多時候,我們的研究顯示他們會拿出來,是因為他們沒辦法說話。他們常常也無法正常吞嚥,所以必須把它拿出來,然後就把它放在頭盔上弄丟或咬壞。所以這也是我們喜歡這項技術的原因。我們可以用不同方式來設計,因為它是更高性能的樹脂,且設計準則的能力遠高於你現在能買到的那種「熱水軟化後咬合成型」(boil and bite)或「成型填充」類的護齒套。
Operator
Operator
And we have reached the end of our question-and-answer session. I will now turn the call back over to Shirley Stacy for any closing remarks.
我們的問答環節到此結束。接下來我會把電話交回給 Shirley Stacy,請她做結語。
Shirley Stacy - Vice President - Corporate Communications & Investor Relations
Shirley Stacy - Vice President - Corporate Communications & Investor Relations
Thank you, everyone, for joining us today. We look forward to meeting and speaking with you at upcoming investor conferences and industry meetings. If you have any follow-up questions or need more information, please contact Align Investor Relations. Thanks, and have a great day.
謝謝各位今天加入我們。我們期待在即將到來的投資人會議與產業會議上與各位見面並交流。若您有任何後續問題或需要更多資訊,請聯絡 Align 投資人關係部門。謝謝,祝各位有美好的一天。
Operator
Operator
Thank you. This concludes today's conference. And you may disconnect your lines at this time. Thank you for your participation.
謝謝。今天的電話會議到此結束。您現在可以掛斷電話線。感謝您的參與。